CETUXIMAB PLUS CISPLATIN, IRINOTECAN, AND THORACIC RADIOTHERAPY AS DEFINITIVE TREATMENT FOR LOCALLY ADVANCED, UNRESECTABLE ESOPHAGEAL CANCER: A PHASE II STUDY OF THE SWOG (S0414)

INTRODUCTION: The specific aims of the study were to evaluate the two-year overall survival (OS) and progression-free survival (PFS), toxicity profile, and best objective response rate in patients with locally advanced, clinically unresectable esophageal cancer receiving cetuximab, cisplatin, irinot...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tomblyn, Michael B., Goldman, Bryan H., Thomas, Charles R., Benedetti, Jacqueline K., Lenz, Heinz-Josef, Mehta, Vivek, Beeker, Thaddeus, Gold, Philip J., Abbruzzese, James L., Blanke, Charles D.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382003/
https://ncbi.nlm.nih.gov/pubmed/22481235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31824c7bed
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares